Patterns of HIV Self-Disclosure in the Oncology Setting

JNCI Cancer Spectr. 2021 Jun 4;5(4):pkab058. doi: 10.1093/jncics/pkab058. eCollection 2021 Aug.

Abstract

Higher rates of cancer treatment toxicity and uniquely poor outcomes following a cancer diagnosis have been reported for persons living with HIV (PLWH). This highlights the importance of active HIV status ascertainment in the oncology setting. Self-disclosure of HIV via electronic questionnaire at patient intake is a low-cost option that has not been thoroughly evaluated. We examined 10 years (2009-2019) of patient intake questionnaire data at Moffitt Cancer Center. Self-disclosure of an HIV diagnosis was not uniform, with 36.1% (n = 299, 95% confidence interval [CI] = 32.8% to 39.4%) of 828 patients disclosing. Identification of HIV through this method was highest for anal cancer patients (66.7%, 95% CI = 57.8% to 74.7%). Self-disclosure among patients with hematopoietic malignancies, the most common diagnosis among PLWH at our institution, was lower (19.4%, 95% CI = 14.6% to 25.0%). Patient characteristics associated with HIV self-disclosure included cancer site, natal gender, and race and ethnicity. Findings highlight gaps to motivate future efforts to increase HIV ascertainment prior to initiating cancer care.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Anus Neoplasms
  • Cancer Care Facilities / statistics & numerical data*
  • Confidence Intervals
  • Ethnicity
  • Female
  • HIV Infections / psychology*
  • HIV Long-Term Survivors / psychology*
  • Hematologic Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Patient Admission / statistics & numerical data*
  • Racial Groups
  • Self Disclosure*
  • Sex Factors
  • Surveys and Questionnaires / statistics & numerical data*